Insys MDL Group Slams Del. Ch. 11 Doc As Fatally Flawed
Opioid multidistrict litigation claimholders branded Insys Therapeutics' Delaware Chapter 11 disclosure statement as "unapprovable" late Friday, in an objection that described the document as an unsupportable and "fatally misleading" effort to...To view the full article, register now.
Already a subscriber? Click here to view full article